EMPA-REG OUTCOME

Empagliflozin Cardiovascular Outcome Event Trial in Type 2 Diabetes

Patient / Population Intervention / Exposition Comparaison Critère de jugement

In 7,020 patients with type 2 diabetes and cardiovascular disease, empagliflozin reduced cardiovascular death compared with placebo.

7 020

Schéma

Double-blind RCT

Critère

CV death, MI or stroke

Pertinence

Résultat3-point MACE HR 0.86; CV death down 38 %; HF hospitalisation down 35 %.

Zinman B, et al. N Engl J Med. 2015;373(22):2117-2128. 10.1056/NEJMoa1504720

Discussion et critique

First cardiovascular-outcomes trial to show an SGLT2-inhibitor benefit — unexpectedly driven by heart failure and CV death, launching the SGLT2i era.